ClinicalTrials.gg

Program

ORKA-002

A development code.

Its studies are mostly in Psoriasis · Hidradenitis Suppurativa, led by Oruka Therapeutics.

Furthest: phase 2, since Mar 11, 20264 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Oruka Therapeutics43 open or runningphase 2since Mar 11, 2026Apr 15, 2025Oct 2027phase 2 · NCT07474792

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT06944379 · 24 enrolled · New Zealand
  2. Mar 11, 2026Phase 2 study in Plaque PsoriasisPhase 2 reachedNCT07474792 · 160 enrolled · United States, Canada
  3. Aug 20, 2026Phase 2 study in Hidradenitis SuppurativaNCT07783542 · 200 planned · United States, Canada
  4. Nov 5, 2026Phase 2 study in Plaque PsoriasisNCT07933783 · 160 planned · United States, Canada

Ahead

  1. Oct 2027Primary completion: phase 2 study in Plaque PsoriasisNCT07474792
  2. Oct 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07783542
  3. Jul 1, 2029Primary completion: phase 2 study in Plaque PsoriasisNCT07933783

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933783Plaque Psoriasis · United States, Canada2By invitationJul 1, 2029160
NCT07783542Hidradenitis Suppurativa · United States, Canada2RecruitingOct 2028200
NCT07474792Plaque Psoriasis · United States, Canada2Active, not recruitingOct 2027160
NCT06944379Healthy Volunteers · New Zealand1CompletedAug 20, 202624

How it is read

Names in the registry

  • “ORKA-002”, 4 entries

Codes read as this program: ORKA002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.